Clinical trial
Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer
NCT00237900 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00237900 |
|---|---|
| Title | Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer |
| Official title | An Open, Single.Centre, Phase I/II Study of ZD1839 (Iressa) in Combination With 5-Fluorouracil, Leucovorin and Radiotherapy in Subjects With Resectable Gastric Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0, Stages II and III) and Histologically-Confirmed Intestinal GC |
| Intervention type | Drug |
| Interventions | Gefitinib, 5-fluorouracil, leucovorin and radiotherapy |
| Enrollment | 34 |
| Start date | Jul 1, 2003 |
| Completion | Feb 1, 2004 |
| First posted | Oct 13, 2005 |
| Last update posted | Apr 23, 2009 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: